Selected Grants
BIO89-100-132 The ENLIGHTEN-Cirrhosis Pro00116849
Clinical TrialPrincipal Investigator · Awarded by 89bio, Inc · 2024 - 2031BIO89-100-131 The ENLIGHTEN-Fibrosis Study Pro00115755. A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.
Clinical TrialPrincipal Investigator · Awarded by 89bio, Inc · 2024 - 2029Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
Clinical TrialCo Investigator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2021 - 2026Generating Evidence to Assess the Optimal Application of NIS2+TM within Real-World Workflows Pro00112444
Clinical TrialPrincipal Investigator · Awarded by The Kinetix Group (TKG) · 2024 - 2025External Relationships
- Guidepoint Clinical
- Madrigal-19
- Novnordisk
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.